Takeda Pharmaceutical Company Limited

Dyax Corporation

Bracco Suisse Sa

Bracco International Bv

Feng Yan

Radhakrishna Pillai

Christophe Arbogast

Philippe Bussat

Sibylle Pochon

Karen E. Linder

Hong Fan

Edmund R. Marinelli

Bo Song

Palaniappa Nanjappan

Mathew A. Von Wronski

Daniel J Sexton

Malini Viswanathan

Ryan Faucette

Andrew Nixon

Christopher TenHoor

Burt Adelman

Jon A Kenniston

Gregory P Conley

Robert Charles Ladner

Tripti Gaur

Christopher Tenhoor

Aaron Sato

Daniel T Dransfield

Yung Chyung

Rolf E Swenson

Kondareddiar Ramalingam

Adrian D Nunn

Karen E Linder

Edmund R Marinelli

Radhakrishna K Pillai

Mathew A Von Wronski

Anthony Williams

Ajay Shrivastava

Stephen R Comeau

Sudha Khurana

Shauna Mason

Guodong Zhang

Jiang Wu

Ryan Iarrobino

Qi-Long Wu

Joseph Biedenkapp

Gul M Mustafa

Mark Szewc

Janja Cosic

Greg Conley

Robert C Ladner

Aaron K Sato

Plasma kallikrein binding proteins and methods of using such proteins are described.

Plasma kallikrein binding proteins

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Monoclonal antibody inhibitor of Factor XIIa

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

Metabolite biomarkers for diseases associated with the contact activation system

Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.

Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

Compositions and methods for treatment of diabetic macular edema

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.

Diagnosis and treatment of autoimmune diseases

RNA biomarkers for hereditary angioedema

Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Protein biomarkers for diseases associated with the contact activation system

Antibodies which bind Fc receptors (FcRn)

Methods of detecting plasma kallikrein

Growing community of inventors

Melrose, MA, United States of America

Daniel J Sexton